Viridian Therapeutics reports Phase 1 data for FcRn inhibitor VRDN‑008 and plans 2027 pivotal trial
Viridian Therapeutics announced that its Phase 1 study of VRDN‑008, an FcRn inhibitor, achieved a 74% reduction in IgG and a half‑life of 15‑18 days in healthy volunteers. The trial reported no serious adverse events or dose‑limiting toxicities. The company said it will launch at least one pivotal trial in mid‑2027, beginning with myasthenia gravis, subject to regulatory feedback, and intends to use the Enable Injections enFuse on‑body injector for quarterly or eight‑week dosing.
Why it matters
The company expects the 2027 pivotal trial to determine whether VRDN‑008 can become a marketed therapy for myasthenia gravis and other autoantibody‑mediated diseases, which could materially affect its future revenue stream.
Key facts
- 1VRDN‑008 reduced IgG levels by up to 74% at peak and maintained the reduction for eight weeks after dosing. investing.com
- 2The drug demonstrated a half‑life of 15‑18 days, up to six times longer than first‑generation Fc fragments. investing.com
- 3No serious adverse events or dose‑limiting toxicities were observed in the Phase 1 trial. investing.com
- 4Viridian plans to start at least one pivotal clinical trial in mid‑2027, beginning with myasthenia gravis, pending regulatory feedback. investing.com
- 5The pivotal trial will compare quarterly dosing at four‑week and eight‑week intervals versus placebo. investing.com
- 6VRDN‑008 will be administered using Enable Injections’ enFuse on‑body injector, for which Viridian holds exclusive global rights. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.